Article
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Oncotarget - 31 Jan 2017
Khelwatty Said, Essapen Sharadah, Bagwan Izhar, Green Margaret, Seddon Alan, Modjtahedi Helmout
Abstract excerpt
Anti-EGFR mAbs cetuximab and panitumumab are routinely used for the treatment of patients with KRAS-wild type metastatic colorectal cancer (mCRC). However, in some patients their efficacy remains modest and with no clear association between the EGFR protein expression determined by PharmDx™ kit, and response to anti-EGFR therapies. Therefore, we investigated the relative expression and predictive value of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.